Target Name: RTCA
NCBI ID: G8634
Review Report on RTCA Target / Biomarker Content of Review Report on RTCA Target / Biomarker
RTCA
Other Name(s): RNA terminal phosphate cyclase domain 1 | RNA 3'-terminal phosphate cyclase | RTC1 | RTCA variant 1 | RNA terminal phosphate cyclase domain-containing protein 1 | RTCA_HUMAN | RNA-3'-phosphate cyclase

Understanding RTCA: A Key Enzyme in Gene Expression and Cell Signaling

RTCA, or RNA terminal phosphate cyclase domain 1, is a protein that plays a critical role in the regulation of gene expression and cell signaling. It is a key enzyme in the RNA polymerase II (RNA-II) complex, which is responsible for generating RNA transcripts from DNA templates in the cell.

The RNA-II complex is a complex protein that includes several subunits, including the RTCA enzyme. RTCA is a nucleotide-binding enzyme that uses ATP to activate the polymerase chain and move the nucleotide along the DNA template. It is also known for its role in the regulation of gene expression and cell signaling, as well as its potential as a drug target.

One of the key features of RTCA is its catalytic activity. It is a highly efficient enzyme that uses ATP to generate a highly specific phosphate group on the RNA template. This phosphate group is then used to activate the polymerase chain and move the nucleotide along the DNA template.

RTCA is also known for its role in the regulation of gene expression. It is a key enzyme in the RNA-II complex, which is responsible for generating RNA transcripts from DNA templates in the cell. It is well established that changes in the level of RTCA activity or its expression levels can have a significant impact on gene expression and protein synthesis.

In addition to its role in gene expression, RTCA is also known for its potential as a drug target. Its catalytic activity and its role in the regulation of gene expression make it an attractive target for small molecules and other therapeutic agents. Many researchers are currently working on developing drugs that can inhibit or modulate RTCA activity in order to treat a variety of diseases.

One of the challenges in studying RTCA is its complex structure. The RNA-II complex is a large and complex protein, and it is difficult to study its mechanisms of action in isolation. However, researchers are making progress in understanding its role in gene expression and cell signaling.

In conclusion, RTCA is a protein that plays a critical role in the regulation of gene expression and cell signaling. Its catalytic activity and its role in the RNA-II complex make it an attractive target for small molecules and other therapeutic agents. Further research is needed to fully understand its mechanisms of action and its potential as a drug target.

Protein Name: RNA 3'-terminal Phosphate Cyclase

Functions: Catalyzes the conversion of 3'-phosphate to a 2',3'-cyclic phosphodiester at the end of RNA. The mechanism of action of the enzyme occurs in 3 steps: (A) adenylation of the enzyme by ATP; (B) transfer of adenylate to an RNA-N3'P to produce RNA-N3'PP5'A; (C) and attack of the adjacent 2'-hydroxyl on the 3'-phosphorus in the diester linkage to produce the cyclic end product. The biological role of this enzyme is unknown but it is likely to function in some aspects of cellular RNA processing

The "RTCA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RTCA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

RTCB | RTEL1 | RTEL1-TNFRSF6B | RTF1 | RTF2 | RTKN | RTKN2 | RTL1 | RTL10 | RTL3 | RTL4 | RTL5 | RTL6 | RTL8A | RTL8B | RTL8C | RTL9 | RTN1 | RTN2 | RTN3 | RTN4 | RTN4IP1 | RTN4R | RTN4RL1 | RTN4RL2 | RTP1 | RTP2 | RTP3 | RTP4 | RTP5 | RTRAF | RTTN | RUBCN | RUBCNL | RUFY1 | RUFY2 | RUFY3 | RUFY4 | RUNDC1 | RUNDC3A | RUNDC3A-AS1 | RUNDC3B | RUNX1 | RUNX1-IT1 | RUNX1T1 | RUNX2 | RUNX2-AS1 | RUNX3 | RUNX3-AS1 | RUSC1 | RUSC1-AS1 | RUSC2 | RUSF1 | RUVBL1 | RUVBL1-AS1 | RUVBL2 | RWDD1 | RWDD2A | RWDD2B | RWDD3 | RWDD3-DT | RWDD4 | RXFP1 | RXFP2 | RXFP3 | RXFP4 | RXRA | RXRB | RXRG | RXYLT1 | Ryanodine receptor | RYBP | RYK | RYR1 | RYR2 | RYR3 | RZZ complex | S100 Calcium Binding Protein | S100A1 | S100A10 | S100A11 | S100A11P1 | S100A12 | S100A13 | S100A14 | S100A16 | S100A2 | S100A3 | S100A4 | S100A5 | S100A6 | S100A7 | S100A7A | S100A7L2 | S100A7P1 | S100A8 | S100A9 | S100B | S100G | S100P